dc.contributor.author | Kostoff, Matthew D. | |
dc.contributor.author | Saseen, Joseph J. | |
dc.contributor.author | Borgelt, Laura M. | |
dc.date.accessioned | 2014-07-21T19:47:27Z | |
dc.date.available | 2014-07-21T19:47:27Z | |
dc.date.issued | 2014-04-28 | |
dc.identifier.citation | Kostoff, Matthew D. et al. (2014). E
valuation of fracture risk and potential
drug holidays for postmenopausal women
on long-term bisphosphonate therapy. International Journal of Women's Health 6:423-428. http://dx.doi.org/10.2147/IJWH.S57549 | |
dc.identifier.issn | 1179-1411 | |
dc.identifier.uri | http://hdl.handle.net/1808/14795 | |
dc.description | This is the publisher's version, also available electronically from http://www.dovepress.com/evaluation-of-fracture-risk-and-potential-drug-holidays-for-postmenopa-peer-reviewed-article-IJWH | |
dc.description.abstract | Study objective: To describe characteristics of postmenopausal women on long-term bisphosphonate therapy who fall into one of four fracture risk categories (low, mild, moderate, high), and to determine the prevalence of women eligible for a drug holiday.
Design: Retrospective electronic health record review.
Setting: Eight primary care clinics within a university-based health care system.
Patients: A total of 201 postmenopausal women of ages 55–89 years, with osteopenia or osteoporosis, prescribed bisphosphonate therapy for >4 years, between October 10, 2002 and September 9, 2012.
Main results: The patients' mean age was 71.4 (±8.2) years; their mean body mass index was 25.3 (±5.6) kg/m2; and 73.1% were white. Seventy-four out of 201 patients (36.8%) were low-risk; 10/201 (5.0%) were mild-risk; 72/201 (35.8%) were moderate-risk; and 45/201 (22.4%) were high-risk. Eighty-one women (40.3%) were eligible for a drug holiday or discontinuation. The estimated drug cost avoided per eligible patient was $574.80. Calcium and/or vitamin D supplementation was documented in 52.7% of women.
Conclusion: More than one-third of postmenopausal women taking long-term bisphosphonate therapy had low fracture risk, and over 40% of our patients were eligble for a drug holiday or discontinuation. These data emphasize the need to accurately assess risk and benefit in patients treated with bisphosphonate therapy. | |
dc.publisher | Dove Medical Press | |
dc.subject | postmenopausal osteoporosis | |
dc.subject | Bisphosphonates | |
dc.subject | Drug holiday | |
dc.subject | Fracture | |
dc.title | Evaluation of fracture risk and potential drug holidays for postmenopausal women on long-term bisphosphonate therapy | |
dc.type | Article | |
kusw.kuauthor | Kostoff, Matthew D. | |
kusw.kudepartment | Pharmacy Practice | |
kusw.oastatus | fullparticipation | |
dc.identifier.doi | 10.2147/IJWH.S57549 | |
kusw.oaversion | Scholarly/refereed, publisher version | |
kusw.oapolicy | This item meets KU Open Access policy criteria. | |
dc.rights.accessrights | openAccess | |